These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20509462)

  • 1. Statins: in the beginning.
    Lyons KS; Harbinson M
    J R Coll Physicians Edinb; 2009 Dec; 39(4):362-4. PubMed ID: 20509462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
    Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
    Atheroscler Suppl; 2004 Oct; 5(3):51-5. PubMed ID: 15531275
    [No Abstract]   [Full Text] [Related]  

  • 3. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. 1976.
    Endo A; Kuroda M; Tanzawa K
    Atheroscler Suppl; 2004 Oct; 5(3):39-42. PubMed ID: 15531273
    [No Abstract]   [Full Text] [Related]  

  • 4. Lowering plasma cholesterol by raising ldl receptors. 1981.
    Brown MS; Goldstein JL
    Atheroscler Suppl; 2004 Oct; 5(3):57-9. PubMed ID: 15531276
    [No Abstract]   [Full Text] [Related]  

  • 5. The discovery and development of HMG-CoA reductase inhibitors.
    Endo A
    J Lipid Res; 1992 Nov; 33(11):1569-82. PubMed ID: 1464741
    [No Abstract]   [Full Text] [Related]  

  • 6. [Contribution of Japanese researchers to the progress of studies in endocrinology and metabolism in the field of internal medicine in the last 100 years: Development of statins].
    Yamamoto A
    Nihon Naika Gakkai Zasshi; 2002 Apr; 91(4):1134-6. PubMed ID: 12056005
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic effects of ml-236B in primary hypercholesterolemia. 1980.
    Yammoto A; Sudo H; Endo A
    Atheroscler Suppl; 2004 Oct; 5(3):43-50. PubMed ID: 15531274
    [No Abstract]   [Full Text] [Related]  

  • 8. Statins have offered great benefits. 2002.
    Yamamoto A
    Atheroscler Suppl; 2004 Oct; 5(3):35-7. PubMed ID: 15531272
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.
    Pedersen TR; Kjekshus J; Berg K; Haghfelt T; Faergeman O; Faergeman G; Pyörälä K; Miettinen T; Wilhelmsen L; Olsson AG; Wedel H;
    Atheroscler Suppl; 2004 Oct; 5(3):81-7. PubMed ID: 15531279
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.
    Bilheimer DW; Grundy SM; Brown MS; Goldstein JL
    Atheroscler Suppl; 2004 Oct; 5(3):61-5. PubMed ID: 15531277
    [No Abstract]   [Full Text] [Related]  

  • 12. Foundations for blockbuster drugs in federally sponsored research.
    Thompson RB
    FASEB J; 2001 Aug; 15(10):1671-6. PubMed ID: 11481212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
    Krasovec M; Elsner P; Burg G
    Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
    Slater EE; MacDonald JS
    Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of statins.
    Stossel TP
    Cell; 2008 Sep; 134(6):903-5. PubMed ID: 18805080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gift from nature: the birth of the statins.
    Endo A
    Nat Med; 2008 Oct; 14(10):1050-2. PubMed ID: 18841147
    [No Abstract]   [Full Text] [Related]  

  • 20. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
    Sirtori CR
    Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.